Literature DB >> 9797228

Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

J L Lopez-Ribot1, R K McAtee, L N Lee, W R Kirkpatrick, T C White, D Sanglard, T F Patterson.   

Abstract

Resistance to fluconazole is becoming an increasing problem in the management of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Strains obtained from five patients developed decreased fluconazole susceptibility over time. DNA strain typing confirmed the high degree of relatedness among isolates from one patient and the variability among isolates from different patients. Expression of genes involved in development of fluconazole resistance was monitored in each isolate using probes specific for ERG11 (lanosterol 14alpha-demethylase), MDR1 (a major facilitator), and CDR (ATP-binding cassette or ABC transporter) genes. Increased expression of CDR genes was detected in the series of isolates from two patients. Isolates from one of the two patients also demonstrated increased ERG11 expression, whereas isolates from the other patient did not. Increased levels of MDR1 mRNA correlated with increased resistance in sequential isolates from another patient. Initial overexpression of MDR1 with subsequent overexpression of CDR genes and a final isolate again overexpressing MDR1 were detected in serial isolates from another patient. In another patient, overexpression of these genes was not detected despite an eightfold increase in fluconazole MIC. In this patient, sequence data of the ERG11 gene revealed no point mutations associated with decreased susceptibility. Five different patterns of gene expression were observed in isolates recovered from five patients who developed resistance. Therefore, these experiments demonstrate that a variety of mechanisms or combinations of mechanisms are associated with the development of fluconazole drug resistance. Additional studies are needed to estimate the frequency and clinical impact of these mechanisms of resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797228      PMCID: PMC105968     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  ABC transporters: from microorganisms to man.

Authors:  C F Higgins
Journal:  Annu Rev Cell Biol       Date:  1992

2.  Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans.

Authors:  M H Lai; D R Kirsch
Journal:  Nucleic Acids Res       Date:  1989-01-25       Impact factor: 16.971

Review 3.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; D Bellens; H Moereels; P A Janssen
Journal:  Biochem Soc Trans       Date:  1990-02       Impact factor: 5.407

4.  Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca3.

Authors:  J Schmid; E Voss; D R Soll
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 5.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 6.  Molecular mechanisms of drug resistance in fungi.

Authors:  H Vanden Bossche; P Marichal; F C Odds
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

Review 7.  Genetics and biochemistry of yeast multidrug resistance.

Authors:  E Balzi; A Goffeau
Journal:  Biochim Biophys Acta       Date:  1994-08-30

8.  Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate.

Authors:  M E Fling; J Kopf; A Tamarkin; J A Gorman; H A Smith; Y Koltin
Journal:  Mol Gen Genet       Date:  1991-06

9.  Fluconazole versus Candida albicans: a complex relationship.

Authors:  J R Graybill; E Montalbo; W R Kirkpatrick; M F Luther; S G Revankar; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 10.  A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport.

Authors:  M D Marger; M H Saier
Journal:  Trends Biochem Sci       Date:  1993-01       Impact factor: 13.807

View more
  87 in total

1.  Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions.

Authors:  W R Kirkpatrick; J L Lopez-Ribot; R K McAtee; T F Patterson
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; J Lowther; A Bryskier; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

4.  Rapid quantification of drug resistance gene expression in Candida albicans by reverse transcriptase LightCycler PCR and fluorescent probe hybridization.

Authors:  Joao P Frade; David W Warnock; Beth A Arthington-Skaggs
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

5.  Proteomic analysis of azole resistance in Candida albicans clinical isolates.

Authors:  Massoumeh Z Hooshdaran; Katherine S Barker; George M Hilliard; Harald Kusch; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 6.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 7.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

8.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

9.  Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity.

Authors:  Rui Li; Rohitashw Kumar; Swetha Tati; Sumant Puri; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

Review 10.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.